DarioHealth has filed a notice of an exempt offering of securities to raise $6.8 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, DarioHealth is raising up to $6,800,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About DarioHealth
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move, which helps to prevent and treat the most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solutions; DarioEngage platform; and Dario blood glucose monitoring system. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and Dario smart diabetes management solutions, including live clinical coaching, content, automated journeys, hardware, and lifestyle coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
To learn more about DarioHealth, visit http://www.dariohealth.com/
DarioHealth Linkedin Page: https://www.linkedin.com/company/dariohealth/
Contact:
Erez Raphael, Chief Executive Officer
833-914-3796
https://www.linkedin.com/in/erezraphael/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.